메뉴 건너뛰기




Volumn 47, Issue 12, 2013, Pages 1666-1674

Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents

Author keywords

body mass index; body surface area; cancer; chemotherapy; dosing; efficacy; excess weight; neoplasm; obesity; overweight; pharmacokinetics; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; TOPOTECAN; TROXACITABINE; VINCRISTINE;

EID: 84891674296     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013509789     Document Type: Review
Times cited : (25)

References (38)
  • 1
    • 0041435762 scopus 로고    scopus 로고
    • Atlanta, GA: American Cancer Society
    • Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013:.
    • (2013) Cancer Facts and Figures 2013
  • 4
    • 0346362456 scopus 로고    scopus 로고
    • Glimepiride pharmacokinetics in obese versus non-obese diabetic patients
    • Shukla UA,Chi EM,Lehr KH.Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.Ann Pharmacother. 2004;38:30-35.
    • (2004) Ann Pharmacother , vol.38 , pp. 30-35
    • Shukla, U.A.1    Chi, E.M.2    Lehr, K.H.3
  • 5
    • 79955681195 scopus 로고    scopus 로고
    • An evaluation of the incidence of myelosuppression in obese patients with a capped body surface area
    • Lopes-Serrao MD,Gressett S,Hall R,Shah S.An evaluation of the incidence of myelosuppression in obese patients with a capped body surface area.J Oncol Pract. 2011;7:13-17.
    • (2011) J Oncol Pract , vol.7 , pp. 13-17
    • Lopes-Serrao, M.D.1    Gressett, S.2    Hall, R.3    Shah, S.4
  • 6
    • 33947320788 scopus 로고    scopus 로고
    • Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study
    • Modesitt SC,Tian C,Kryscio Ret al.Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.Gynecol Oncol. 2007;105:59-65.
    • (2007) Gynecol Oncol , vol.105 , pp. 59-65
    • Modesitt, S.C.1    Tian, C.2    Kryscio, R.3
  • 7
    • 34247851095 scopus 로고    scopus 로고
    • Chemotherapy dose intensity and quality cancer care
    • Lyman GH.Chemotherapy dose intensity and quality cancer care.Oncology (Williston Park). 2006;20:16-25.
    • (2006) Oncology (Williston Park) , vol.20 , pp. 16-25
    • Lyman, G.H.1
  • 8
    • 0029824018 scopus 로고    scopus 로고
    • Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541
    • Rosner GL,Hargis JB,Hollis DRet al.Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.J Clin Oncol. 1996;14:3000-3008.
    • (1996) J Clin Oncol , vol.14 , pp. 3000-3008
    • Rosner, G.L.1    Hargis, J.B.2    Hollis, D.R.3
  • 9
    • 0035004363 scopus 로고    scopus 로고
    • Are medical oncologists biased in their treatment of the large woman with breast cancer?
    • Madarnas Y,Sawka CA,Franssen E,Bjarnason GA.Are medical oncologists biased in their treatment of the large woman with breast cancer?.Breast Cancer Res Treat. 2001;66:123-133.
    • (2001) Breast Cancer Res Treat , vol.66 , pp. 123-133
    • Madarnas, Y.1    Sawka, C.A.2    Franssen, E.3    Bjarnason, G.A.4
  • 10
    • 1442332174 scopus 로고    scopus 로고
    • Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
    • Meyerhardt JA,Tepper JE,Niedzwiecki Det al.Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.J Clin Oncol. 2004;22:648-657.
    • (2004) J Clin Oncol , vol.22 , pp. 648-657
    • Meyerhardt, J.A.1    Tepper, J.E.2    Niedzwiecki, D.3
  • 11
    • 25144466036 scopus 로고    scopus 로고
    • Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
    • Colleoni M,Li S,Gelber RDet al.Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.Lancet. 2005;366:1108-1110.
    • (2005) Lancet , vol.366 , pp. 1108-1110
    • Colleoni, M.1    Li, S.2    Gelber, R.D.3
  • 12
    • 84862986506 scopus 로고    scopus 로고
    • Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline
    • Griggs JJ,Mangu PB,Anderson Het al.Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2012;30:1553-1561.
    • (2012) J Clin Oncol , vol.30 , pp. 1553-1561
    • Griggs, J.J.1    Mangu, P.B.2    Anderson, H.3
  • 13
    • 84867600008 scopus 로고    scopus 로고
    • Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults
    • Pai MP.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Pharmacotherapy. 2012;32:856-868.
    • (2012) Pharmacotherapy , vol.32 , pp. 856-868
    • Pai, M.P.1
  • 14
    • 84876262274 scopus 로고    scopus 로고
    • Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
    • Hall RG,Swancutt MA,Meek C,Leff R,Gumbo T.Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.Antimicrob Agents Chemother. 2013;27:2259-2264.
    • (2013) Antimicrob Agents Chemother , vol.27 , pp. 2259-2264
    • Hall, R.G.1    Swancutt, M.A.2    Meek, C.3    Leff, R.4    Gumbo, T.5
  • 15
    • 80054695467 scopus 로고    scopus 로고
    • Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people
    • Hall RG,Swancutt MA,Gumbo T.Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people.Antimicrob Agents Chemother. 2011;55:5107-5112.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 5107-5112
    • Hall, R.G.1    Swancutt, M.A.2    Gumbo, T.3
  • 16
    • 84857183281 scopus 로고    scopus 로고
    • Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
    • Hall RG,Swancutt MA,Meek C,Leff RD,Gumbo T.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.Antimicrob Agents Chemother. 2012;56:1502-1507.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 1502-1507
    • Hall, R.G.1    Swancutt, M.A.2    Meek, C.3    Leff, R.D.4    Gumbo, T.5
  • 18
    • 36048936308 scopus 로고    scopus 로고
    • Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    • Sparreboom A,Wolff AC,Mathijssen RHet al.Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.J Clin Oncol. 2007;25:4707-4713.
    • (2007) J Clin Oncol , vol.25 , pp. 4707-4713
    • Sparreboom, A.1    Wolff, A.C.2    Mathijssen, R.H.3
  • 19
    • 28844446324 scopus 로고    scopus 로고
    • Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia
    • Herrington JD,Tran HT,Riggs MW.Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.Cancer Chemother Pharmacol. 2006;57:241-247.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 241-247
    • Herrington, J.D.1    Tran, H.T.2    Riggs, M.W.3
  • 20
    • 0023270126 scopus 로고
    • Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
    • Powis G,Reece P,Ahmann DL,Ingle JN.Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.Cancer Chemother Pharmacol. 1987;20:219-222.
    • (1987) Cancer Chemother Pharmacol , vol.20 , pp. 219-222
    • Powis, G.1    Reece, P.2    Ahmann, D.L.3    Ingle, J.N.4
  • 23
    • 1942488208 scopus 로고    scopus 로고
    • Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
    • Rudek MA,Sparreboom A,Garrett-Mayer ESet al.Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.Eur J Cancer. 2004;40:1170-1178.
    • (2004) Eur J Cancer , vol.40 , pp. 1170-1178
    • Rudek, M.A.1    Sparreboom, A.2    Garrett-Mayer, E.S.3
  • 24
    • 77957267066 scopus 로고    scopus 로고
    • Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass
    • Barpe DR,Rosa DD,Froehlich PE.Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.Eur J Pharm Sci. 2010;41:458-463.
    • (2010) Eur J Pharm Sci , vol.41 , pp. 458-463
    • Barpe, D.R.1    Rosa, D.D.2    Froehlich, P.E.3
  • 25
    • 0026737548 scopus 로고
    • Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study
    • Eksborg S,Hardell L,Bengtsson NO,Sjodin M,Elfsson B.Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study.Med Oncol Tumor Pharmacother. 1992;9:75-80.
    • (1992) Med Oncol Tumor Pharmacother , vol.9 , pp. 75-80
    • Eksborg, S.1    Hardell, L.2    Bengtsson, N.O.3    Sjodin, M.4    Elfsson, B.5
  • 26
    • 0031860380 scopus 로고    scopus 로고
    • Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation
    • Gurney HP,Ackland S,Gebski V,Farrell G.Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.J Clin Oncol. 1998;16:2299-2304.
    • (1998) J Clin Oncol , vol.16 , pp. 2299-2304
    • Gurney, H.P.1    Ackland, S.2    Gebski, V.3    Farrell, G.4
  • 27
    • 0026070138 scopus 로고
    • Disposition of high-dose methotrexate in an obese cancer patient
    • Fleming RA,Eldridge RM,Johnson CE,Stewart CF.Disposition of high-dose methotrexate in an obese cancer patient.Cancer. 1991;68:1247-1250.
    • (1991) Cancer , vol.68 , pp. 1247-1250
    • Fleming, R.A.1    Eldridge, R.M.2    Johnson, C.E.3    Stewart, C.F.4
  • 28
    • 77955802588 scopus 로고    scopus 로고
    • Estimating the glomerular filtration rate in obese adult patients for drug dosing
    • Pai MP.Estimating the glomerular filtration rate in obese adult patients for drug dosing.Adv Chronic Kidney Dis. 2010;17:e53-e62.
    • (2010) Adv Chronic Kidney Dis , vol.17
    • Pai, M.P.1
  • 29
    • 63449109827 scopus 로고    scopus 로고
    • Estimation of creatinine clearance in morbidly obese patients
    • Demirovic JA,Pai AB,Pai MP.Estimation of creatinine clearance in morbidly obese patients.Am J Health Syst Pharm. 2009;66:642-648.
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 642-648
    • Demirovic, J.A.1    Pai, A.B.2    Pai, M.P.3
  • 30
    • 44549088304 scopus 로고    scopus 로고
    • Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study
    • Wright JD,Tian C,Mutch DGet al.Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2008;109:353-358.
    • (2008) Gynecol Oncol , vol.109 , pp. 353-358
    • Wright, J.D.1    Tian, C.2    Mutch, D.G.3
  • 31
    • 66149190687 scopus 로고    scopus 로고
    • A universal formula based on cystatin C to perfrom individual dosing of carboplatin in normal weight, underweight, and obese patients
    • Schmitt A,Gladieff L,Lansiaux Aet al.A universal formula based on cystatin C to perfrom individual dosing of carboplatin in normal weight, underweight, and obese patients.Clin Cancer Res. 2009;15:3633-3639.
    • (2009) Clin Cancer Res , vol.15 , pp. 3633-3639
    • Schmitt, A.1    Gladieff, L.2    Lansiaux, A.3
  • 32
    • 34548119532 scopus 로고    scopus 로고
    • Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient
    • Ritzmo C,Soderhall S,Karlen J,Nygren H,Eksborg S.Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.Pediatr Hematol Oncol. 2007;24:437-445.
    • (2007) Pediatr Hematol Oncol , vol.24 , pp. 437-445
    • Ritzmo, C.1    Soderhall, S.2    Karlen, J.3    Nygren, H.4    Eksborg, S.5
  • 33
    • 67349169750 scopus 로고    scopus 로고
    • Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
    • Thompson PA,Rosner GL,Matthay KKet al.Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.Cancer Chemother Pharmacol. 2009;64:243-251.
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 243-251
    • Thompson, P.A.1    Rosner, G.L.2    Matthay, K.K.3
  • 34
    • 0036161278 scopus 로고    scopus 로고
    • Peak plasma concentrations of doxorubicin in children with acute lympoblastic leukemia or non-Hodkin lymphoma
    • Hempel G,Flege S,Wurthwein G,Boos J.Peak plasma concentrations of doxorubicin in children with acute lympoblastic leukemia or non-Hodkin lymphoma.Cancer Chemother Pharmacol. 2002;49:133-141.
    • (2002) Cancer Chemother Pharmacol , vol.49 , pp. 133-141
    • Hempel, G.1    Flege, S.2    Wurthwein, G.3    Boos, J.4
  • 35
    • 0037962010 scopus 로고    scopus 로고
    • Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
    • Meyerhardt JA,Catalano PJ,Haller DGet al.Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.Cancer. 2003;98:484-495.
    • (2003) Cancer , vol.98 , pp. 484-495
    • Meyerhardt, J.A.1    Catalano, P.J.2    Haller, D.G.3
  • 36
    • 33644846283 scopus 로고    scopus 로고
    • Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
    • Haller DG,Catalano PJ,Macdonald JSet al.Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.J Clin Oncol. 2005;23:8671-8678.
    • (2005) J Clin Oncol , vol.23 , pp. 8671-8678
    • Haller, D.G.1    Catalano, P.J.2    Macdonald, J.S.3
  • 37
    • 77950628999 scopus 로고    scopus 로고
    • Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice
    • Behan JW,Avramis VI,Yun JP,Louie SG,Mittelman SD.Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.Pharmacol Res. 2010;61:385-390.
    • (2010) Pharmacol Res , vol.61 , pp. 385-390
    • Behan, J.W.1    Avramis, V.I.2    Yun, J.P.3    Louie, S.G.4    Mittelman, S.D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.